ATYR PHARMA INC (ATYR) Fundamental Analysis & Valuation

NASDAQ:ATYR • US0021202025

Current stock price

0.815 USD
-0.07 (-7.54%)
At close:
0.8313 USD
+0.02 (+2%)
After Hours:

This ATYR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATYR Profitability Analysis

1.1 Basic Checks

  • In the past year ATYR has reported negative net income.
  • ATYR had a negative operating cash flow in the past year.
  • ATYR had negative earnings in each of the past 5 years.
  • ATYR had a negative operating cash flow in each of the past 5 years.
ATYR Yearly Net Income VS EBIT VS OCF VS FCFATYR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -79.69%, ATYR is not doing good in the industry: 66.80% of the companies in the same industry are doing better.
  • ATYR has a Return On Equity of -109.84%. This is comparable to the rest of the industry: ATYR outperforms 42.86% of its industry peers.
Industry RankSector Rank
ROA -79.69%
ROE -109.84%
ROIC N/A
ROA(3y)-62.53%
ROA(5y)-52.83%
ROE(3y)-85.62%
ROE(5y)-70.24%
ROIC(3y)N/A
ROIC(5y)N/A
ATYR Yearly ROA, ROE, ROICATYR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • ATYR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATYR Yearly Profit, Operating, Gross MarginsATYR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ATYR Health Analysis

2.1 Basic Checks

  • ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ATYR has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ATYR has more shares outstanding
  • Compared to 1 year ago, ATYR has an improved debt to assets ratio.
ATYR Yearly Shares OutstandingATYR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
ATYR Yearly Total Debt VS Total AssetsATYR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • ATYR has an Altman-Z score of -9.01. This is a bad value and indicates that ATYR is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -9.01, ATYR is doing worse than 70.85% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that ATYR is not too dependend on debt financing.
  • ATYR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. ATYR outperforms 48.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.01
ROIC/WACCN/A
WACC8.84%
ATYR Yearly LT Debt VS Equity VS FCFATYR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 5.30 indicates that ATYR has no problem at all paying its short term obligations.
  • ATYR has a Current ratio (5.30) which is comparable to the rest of the industry.
  • A Quick Ratio of 5.30 indicates that ATYR has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.30, ATYR is in line with its industry, outperforming 59.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.3
ATYR Yearly Current Assets VS Current LiabilitesATYR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ATYR Growth Analysis

3.1 Past

  • ATYR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.20%, which is quite good.
  • The Revenue for ATYR has decreased by -19.15% in the past year. This is quite bad
  • ATYR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -55.14% yearly.
EPS 1Y (TTM)9.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)-19.15%
Revenue growth 3Y-73.65%
Revenue growth 5Y-55.14%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 30.05% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ATYR will show a very strong growth in Revenue. The Revenue will grow by 415.19% on average per year.
EPS Next Y24.63%
EPS Next 2Y17.42%
EPS Next 3Y22.13%
EPS Next 5Y30.05%
Revenue Next Year18728.6%
Revenue Next 2Y2099.5%
Revenue Next 3Y810.88%
Revenue Next 5Y415.19%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ATYR Yearly Revenue VS EstimatesATYR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
ATYR Yearly EPS VS EstimatesATYR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. ATYR Valuation Analysis

4.1 Price/Earnings Ratio

  • ATYR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATYR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATYR Price Earnings VS Forward Price EarningsATYR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATYR Per share dataATYR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • ATYR's earnings are expected to grow with 22.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.42%
EPS Next 3Y22.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATYR Dividend Analysis

5.1 Amount

  • ATYR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATYR Fundamentals: All Metrics, Ratios and Statistics

ATYR PHARMA INC

NASDAQ:ATYR (3/18/2026, 5:20:14 PM)

After market: 0.8313 +0.02 (+2%)

0.815

-0.07 (-7.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-05
Inst Owners55.16%
Inst Owner ChangeN/A
Ins Owners1.42%
Ins Owner Change4.28%
Market Cap79.86M
Revenue(TTM)190.00K
Net Income(TTM)-74.12M
Analysts74.12
Price Target6.48 (695.09%)
Short Float %19.47%
Short Ratio9.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.75%
Min EPS beat(2)-38.81%
Max EPS beat(2)25.3%
EPS beat(4)2
Avg EPS beat(4)-4.54%
Min EPS beat(4)-38.81%
Max EPS beat(4)25.3%
EPS beat(8)5
Avg EPS beat(8)1.37%
EPS beat(12)8
Avg EPS beat(12)6.04%
EPS beat(16)10
Avg EPS beat(16)4.92%
Revenue beat(2)0
Avg Revenue beat(2)-93.01%
Min Revenue beat(2)-100%
Max Revenue beat(2)-86.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)15.18%
EPS NQ rev (3m)15.18%
EPS NY rev (1m)7.13%
EPS NY rev (3m)6.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-12.5%
Revenue NY rev (3m)-12.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 420.33
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.69%
ROE -109.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.53%
ROA(5y)-52.83%
ROE(3y)-85.62%
ROE(5y)-70.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.6%
Cap/Sales 40.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.3
Altman-Z -9.01
F-Score2
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)244.26%
Cap/Depr(5y)296.1%
Cap/Sales(3y)420.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y24.63%
EPS Next 2Y17.42%
EPS Next 3Y22.13%
EPS Next 5Y30.05%
Revenue 1Y (TTM)-19.15%
Revenue growth 3Y-73.65%
Revenue growth 5Y-55.14%
Sales Q2Q%N/A
Revenue Next Year18728.6%
Revenue Next 2Y2099.5%
Revenue Next 3Y810.88%
Revenue Next 5Y415.19%
EBIT growth 1Y-14.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.06%
EBIT Next 3Y-22.02%
EBIT Next 5YN/A
FCF growth 1Y10.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.32%
OCF growth 3YN/A
OCF growth 5YN/A

ATYR PHARMA INC / ATYR Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ATYR PHARMA INC (ATYR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATYR.


What is the valuation status for ATYR stock?

ChartMill assigns a valuation rating of 1 / 10 to ATYR PHARMA INC (ATYR). This can be considered as Overvalued.


How profitable is ATYR PHARMA INC (ATYR) stock?

ATYR PHARMA INC (ATYR) has a profitability rating of 0 / 10.


Can you provide the financial health for ATYR stock?

The financial health rating of ATYR PHARMA INC (ATYR) is 3 / 10.